Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

di Attard, Gerhardt, Reid, Alison H.M., A’Hern, Roger, Parker, Christopher, Oommen, Nikhil Babu, Folkerd, Elizabeth, Messiou, Christina, Molife, L. Rhoda, Maier, Gal, Thompson, Emilda, Olmos, David, Sinha, Rajesh, Lee, Gloria, Dowsett, Mitch, Kaye, Stan B., Dearnaley, David, Kheoh, Thian, Molina, Arturo, de Bono, Johann S.
Pubblicazione 2009

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

di Olmos, David, Brewer, Daniel, Clark, Jeremy, Danila, Daniel C, Parker, Chris, Attard, Gerhardt, Fleisher, Martin, Reid, Alison H M, Castro, Elena, Sandhu, Shahneen K, Barwell, Lorraine, Oommen, Nikhil Babu, Carreira, Suzanne, Drake, Charles G, Jones, Robert, Cooper, Colin S, Scher, Howard I, de Bono, Johann S
Pubblicato in Lancet Oncol (2012)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

di Lozano, Rebeca, Lorente, David, Aragon, Isabel M., Romero-Laorden, Nuria, Nombela, Paz, Mateo, Joaquim, Reid, Alison H. M., Cendón, Ylenia, Bianchini, Diletta, Llacer, Casilda, Sandhu, Shahneen K., Sharp, Adam, Rescigno, Pasquale, Garcés, Teresa, Pacheco, Maria I., Flohr, Penelope, Massard, Christophe, López-Casas, Pedro P., Castro, Elena, de Bono, Johann S., Olmos, David
Pubblicato in Cancers (Basel) (2021)

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

di Reid, Alison H.M., Attard, Gerhardt, Danila, Daniel C., Oommen, Nikhil Babu, Olmos, David, Fong, Peter C., Molife, L. Rhoda, Hunt, Joanne, Messiou, Christina, Parker, Christopher, Dearnaley, David, Swennenhuis, Joost F., Terstappen, Leon W.M.M., Lee, Gloria, Kheoh, Thian, Molina, Arturo, Ryan, Charles J., Small, Eric, Scher, Howard I., de Bono, Johann S.
Pubblicazione 2010